JAMA · 2022
Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement.
СтатьяКлинические рекомендацииПоддержка службы здравоохранения СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
US Preventive Services Task Force, Davidson Karina W, Barry Michael J, Mangione Carol M, Cabana Michael, Caughey Aaron B, Davis Esa M, Donahue Katrina E, Doubeni Chyke A, Epling John W, Kubik Martha, Li Li, Ogedegbe Gbenga, Pbert Lori, Silverstein Michael, Stevermer James, Tseng Chien-Wen, Wong John B
Аннотация
IMPORTANCE: Atrial fibrillation (AF) is the most common cardiac arrhythmia. The prevalence of AF increases with age, from less than 0.2% in adults younger than 55 years to about 10% in those 85 years or older, with a higher prevalence in men than in women. It is uncertain whether the prevalence of AF differs by race and ethnicity. Atrial fibrillation is a major risk factor for ischemic stroke and is associated with a substantial increase in the risk of stroke. Approximately 20% of patients who have a stroke associated with AF are first diagnosed with AF at the time of the stroke or shortly thereafter.
OBJECTIVE: To update its 2018 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the benefits and harms of screening for AF in older adults, the accuracy of screening tests, the effectiveness of screening tests to detect previously undiagnosed AF compared with usual care, and the benefits and harms of anticoagulant therapy for the treatment of screen-detected AF in older adults.
POPULATION: Adults 50 years or older without a diagnosis or symptoms of AF and without a history of transient ischemic attack or stroke.
EVIDENCE ASSESSMENT: The USPSTF concludes that evidence is lacking, and the balance of benefits and harms of screening for AF in asymptomatic adults cannot be determined.
RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AF. (I statement).
OBJECTIVE: To update its 2018 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the benefits and harms of screening for AF in older adults, the accuracy of screening tests, the effectiveness of screening tests to detect previously undiagnosed AF compared with usual care, and the benefits and harms of anticoagulant therapy for the treatment of screen-detected AF in older adults.
POPULATION: Adults 50 years or older without a diagnosis or symptoms of AF and without a history of transient ischemic attack or stroke.
EVIDENCE ASSESSMENT: The USPSTF concludes that evidence is lacking, and the balance of benefits and harms of screening for AF in asymptomatic adults cannot be determined.
RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AF. (I statement).